Evidence snapshot
A synthetic growth-hormone secretagogue. It stimulates a release signal rather than supplying growth hormone itself; measuring that signal is different from measuring added muscle or better sleep.
Why it stands out
Interest centers on the link between the GH axis, physical recovery and metabolism. Its selectivity in early experiments is part of the appeal, while the next meaningful step is demonstrating useful outcomes in people.
How it may work
It stimulates the ghrelin receptor to trigger pituitary growth-hormone release.
What studies found
A 1999 study in healthy male volunteers measured ipamorelin concentrations alongside growth-hormone release after controlled infusions. It characterized the drug's short-term hormone response and disposition, rather than testing a training, sleep or fat-loss program.
What the evidence means
A measurable GH response confirms biological activity. It does not by itself establish durable improvements in strength, body composition or sleep, and claims about combinations with CJC-1295 or tesamorelin need evidence for those combinations.
Safety and limitations
Long-term human safety remains incompletely characterized. GH-axis stimulation raises questions about glucose handling, fluid retention and effects in people with underlying endocrine disease. Early selectivity findings do not mean side-effect-free use.
Current status
Ipamorelin is not an FDA-approved drug. The 2027 WADA list names ipamorelin among growth-hormone secretagogues in class S2.2.4, prohibited at all times in tested sport.
Common questions
Is it the same as sermorelin? No. Ipamorelin acts through the ghrelin receptor; sermorelin uses the GHRH receptor. Both involve GH release, but different receptors do not automatically make a combined regimen better.
Personal accounts, not clinical results
A user discussing a tesamorelin/ipamorelin stack reports improved definition and recovery, alongside resistance training and retatrutide. It captures the appeal of these combinations, but those simultaneous changes prevent assigning the result to ipamorelin alone.